Free Trial

Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

$138.08
+2.37 (+1.75%)
(As of 07/12/2024 ET)

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$179.00
29.63% Upside
High Forecast$262.00
Average Forecast$179.00
Low Forecast$113.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$179.00$179.44$173.25$148.09
Forecasted Upside29.63% Upside36.79% Upside29.89% Upside54.94% Upside
Get Ascendis Pharma A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

ASND Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ASND Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ascendis Pharma A/S Stock vs. The Competition

TypeAscendis Pharma A/SMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside29.63% Upside991.61% Upside9.39% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/25/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Werber
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$156.00 ➝ $175.00+35.25%
5/31/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$200.00+45.51%
5/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$116.00 ➝ $140.00+13.97%
5/15/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$173.00+38.60%
5/3/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $262.00+90.96%
5/3/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$167.00 ➝ $170.00+23.84%
2/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$146.00 ➝ $182.00+29.12%
2/8/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$207.00 ➝ $225.00+61.53%
12/20/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$150.00+21.72%
10/9/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
9/7/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$107.00 ➝ $113.00+8.69%
4/28/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
4/5/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
4/3/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
11/14/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$168.00 ➝ $148.00+33.57%
10/20/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$174.00+59.63%
8/30/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$166.00+88.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:18 AM ET.

ASND Forecast - Frequently Asked Questions

What is Ascendis Pharma A/S's forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Ascendis Pharma A/S is $179.00, with a high forecast of $262.00 and a low forecast of $113.00.

Should I buy or sell Ascendis Pharma A/S stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares.

Does Ascendis Pharma A/S's stock price have much upside?

According to analysts, Ascendis Pharma A/S's stock has a predicted upside of 36.65% based on their 12-month stock forecasts.

Has Ascendis Pharma A/S been upgraded by Wall Street analysts recently?

Over the previous 90 days, Ascendis Pharma A/S's stock had 1 upgrade by analysts.

What analysts cover Ascendis Pharma A/S?

Ascendis Pharma A/S has been rated by research analysts at Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, TD Cowen, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Ascendis Pharma A/S more than its competitors?

Analysts like Ascendis Pharma A/S more than other "medical" companies. The consensus rating score for Ascendis Pharma A/S is 2.90 while the average consensus rating score for "medical" companies is 2.71. Learn more on how ASND compares to other companies.


This page (NASDAQ:ASND) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners